研究者詳細 - 田中　哲人

論文 - 田中　哲人

分割表示 229 件中 201 - 220 件目／全件表示 >>

Excimer laser facilitated coronary angioplasty of a heavy calcified lesion treated with bioresorbable scaffolds. 査読有り

Mangieri A, Jabbour RJ, Tanaka A, Aurelio A, Colombo A, Latib A

Journal of cardiovascular medicine (Hagerstown, Md.) 17 巻頁： e149 - e150 2016年

Clinical outcomes following target lesion revascularization for bioresorbable scaffold failure. 査読有り

Tanaka A, Ruparelia N, Kawamoto H, Sticchi A, Figini F, Carlino M, Chieffo A, Montorfano M, Latib A, Colombo A

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 87 巻 ( 5 ) 頁： 832 - 6 2016年

A super high-pressure balloon solution for a non-dilatable in-stent restenosis. 査読有り

Tanaka A, Jabbour RJ, Kawamoto H, Latib A, Colombo A

International journal of cardiology 203 巻頁： 357 - 9 2016年

Very Late Restenosis After Bioresorbable Scaffold Implantation Due to Simultaneous External Compression of the Scaffold and Intrascaffold Tissue Growth. 査読有り Open Access

Tanaka A, Ruparelia N, Kawamoto H, Latib A, Colombo A

JACC. Cardiovascular interventions 9 巻 ( 2 ) 頁： e15 - 7 2016年

Long-Term Outcomes After Transcatheter Aortic Valve Implantation from a Single High-Volume Center (The Milan Experience). 査読有り

Ruparelia N, Latib A, Buzzatti N, Giannini F, Figini F, Mangieri A, Regazzoli D, Stella S, Sticchi A, Kawamoto H, Tanaka A, Agricola E, Monaco F, Castiglioni A, Ancona M, Cioni M, Spagnolo P, Chieffo A, Montorfano M, Alfieri O, Colombo A

The American journal of cardiology 117 巻 ( 5 ) 頁： 813 - 9 2016年

Clinical outcomes following bioresorbable scaffold implantation in small vessels. 査読有り

Tanaka A, Ruparelia N, Kawamoto H, Sticchi A, Sato K, Miyazaki T, Naganuma T, Chieffo A, Carlino M, Montorfano M, Latib A, Colombo A

International journal of cardiology 207 巻頁： 59 - 61 2016年

Vascular Healing of a False Lumen After Bioresorbable Scaffold Implantation. 査読有り Open Access

Kawamoto H, Jabbour RJ, Tanaka A, Latib A, Colombo A

Circulation. Cardiovascular interventions 9 巻 ( 2 ) 頁： e003498 2016年

The Bioresorbable Scaffold: Will Oversizing Affect Outcomes? 査読有り Open Access

Kawamoto H, Jabbour RJ, Tanaka A, Latib A, Colombo A

JACC. Cardiovascular interventions 9 巻 ( 3 ) 頁： 299 - 300 2016年

Contained coronary rupture following bioresorbable scaffold implantation in a small vessel. 査読有り

Kawamoto H, Jabbour RJ, Tanaka A, Latib A, Colombo A

International journal of cardiology 209 巻頁： 24 - 5 2016年

Transcatheter aortic valve implantation in intermediate- and low-risk populations: An inevitable progression? 査読有り

Jabbour RJ, Pagnesi M, Kawamoto H, Tanaka A, Regazzoli D, Mangieri A, Ancona M, Monaco F, Agricola E, Spagnolo P, Castiglioni A, De Angelis G, Chieffo A, Montorfano M, Colombo A, Latib A

International journal of cardiology 210 巻頁： 35 - 7 2016年

Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience. 査読有り Open Access

Moscarella E, Ielasi A, Granata F, Coscarelli S, Stabile E, Latib A, Cortese B, Tespili M, Tanaka A, Capozzolo C, Caliendo L, Colombo A, Varricchio A

Circulation. Cardiovascular interventions 9 巻 ( 4 ) 頁： e003148 2016年

Illustration of the Resorption Process Between 2 Different Overlapping Bioresorbable Scaffolds. 査読有り

Tanaka A, Jabbour RJ, Kawamoto H, Latib A, Colombo A

JACC. Cardiovascular imaging 9 巻 ( 12 ) 頁： 1469 - 1470 2016年

Bioresorbable scaffold failure for recurrent restenosis at multi-layered stent fracture. 査読有り

Tanaka A, Jabbour RJ, Kawamoto H, Latib A, Colombo A

International journal of cardiology 214 巻頁： 360 - 1 2016年

Usefulness of Predilation Before Transcatheter Aortic Valve Implantation. 査読有り

Pagnesi M, Jabbour RJ, Latib A, Kawamoto H, Tanaka A, Regazzoli D, Mangieri A, Montalto C, Ancona MB, Giannini F, Chieffo A, Montorfano M, Monaco F, Castiglioni A, Alfieri O, Colombo A

The American journal of cardiology 118 巻 ( 1 ) 頁： 107 - 12 2016年

Clinical outcomes following bifurcation double-stenting with bioresorbable scaffolds. 査読有り

Tanaka A, Latib A, Kawamoto H, Jabbour RJ, Mangieri A, Pagnesi M, Montalto C, Regazzoli D, Ancona M, Chieffo A, Carlino M, Montorfano M, Colombo A

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 88 巻 ( 6 ) 頁： 854 - 862 2016年

Impact of the statin escape phenomenon on long-term clinical outcomes in patients with acute myocardial infarction: Subgroup analysis of the Nagoya Acute Myocardial Infarction Study (NAMIS) 査読有り

Ota Tomoyuki, Ishii Hideki, Suzuki Susumu, Shibata Yohei, Tatami Yosuke, Harata Shingo, Shimbo Yusaku, Takayama Yohei, Tanaka Akihito, Kawamura Yoshihiro, Osugi Naohiro, Maeda Kengo, Kondo Takahisa, Murohara Toyoaki

ATHEROSCLEROSIS 242 巻 ( 1 ) 頁： 155 - 160 2015年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Atherosclerosis

Background: Statins are reportedly effective in the primary and secondary prevention of cardiovascular disease, mainly due to their ability to aggressively reduce low-density lipoprotein cholesterol (LDL-C) levels. However, patients sometimes exhibit the so-called "statin escape" phenomenon. The purpose of our study was to investigate the impact of the statin escape phenomenon on long-term clinical outcomes in patients with acute myocardial infarction (AMI). Method: This was a subgroup analysis of 1144 patients from the Nagoya Acute Myocardial Infarction Study (NAMIS) treated between January 2004 and December 2012. We analyzed 660 patients who initiated statin treatment after AMI. Statin escape phenomenon was defined as an increase in the LDL-C levels during the 9-month treatment period by >10% of the initial values after 4 weeks of initiating statin treatment. Patients were divided into two groups depending on whether they exhibited the statin escape phenomenon, with 474 patients in the non-escape group and 186 patients in the escape group. Result: Compared to the non-escape group, the escape group showed significantly lower LDL-C levels at 4 weeks after treatment initiation (81.3 ± 20.1 mg/dL vs. 101.1 ± 25.4 mg/dL, P < 0.01). By contrast, the escape group showed significantly higher LDL-C levels at 9 months after treatment initiation (105.8 ± 28.3 mg/dL vs. 90.3 ± 22.6 mg/dL, P < 0.01). Major adverse cardiac and cerebrovascular events (MACCE; a composite of all-cause death, MI, and stroke) were more frequent in the escape group than in the non-escape group (10.8% vs. 6.1%, P = 0.03). Multivariate analysis showed that statin escape phenomenon was an independent predictor of MACCE (hazard ratio: 2.02, 95% confidence interval: 1.11-3.66, P = 0.02). Conclusion: Statin escape phenomenon may be an independent predictor of long-term clinical outcomes in AMI patients.

DOI： 10.1016/j.atherosclerosis.2015.07.012

Relation Between Paradoxical Decrease in High-Density Lipoprotein Cholesterol Levels After Statin Therapy and Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction 査読有り

Ota Tomoyuki, Ishii Hideki, Suzuki Susumu, Tanaka Akihito, Shibata Yohei, Tatami Yosuke, Harata Shingo, Shimbo Yusaku, Takayama Yohei, Kawamura Yoshihiro, Osugi Naohiro, Maeda Kengo, Kondo Takahisa, Murohara Toyoaki

AMERICAN JOURNAL OF CARDIOLOGY 115 巻 ( 4 ) 頁： 411 - 416 2015年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：American Journal of Cardiology

Statin therapy moderately increases high-density lipoprotein cholesterol (HDL-C) levels. Contrary to this expectation, a paradoxical decrease in HDL-C levels after statin therapy is seen in some patients. We evaluated 724 patients who newly started treatment with statins after acute myocardial infarction (AMI). These patients were divided into 2 groups according to change in HDL-C levels between baseline and 6 to 9 months after initial AMI (ΔHDL). In total, 620 patients had increased HDL-C levels and 104 patients had decreased HDL-C levels. Both groups achieved follow-up low-density lipoprotein cholesterol levels <100 mg/dl. Adverse cardiovascular events (a composite of all-cause death, myocardial infarction, and stroke) have more frequently occurred in the decreased HDL group compared with the increased HDL group (15.4% vs 7.1%, p = 0.01). Multivariate analysis showed that decreased HDL, onset to balloon time, and multivessel disease were the independent predictors of adverse cardiovascular events (hazard ratio [HR] 1.95, 95% confidence interval [CI] 1.08 to 3.52; HR 1.05, 95% CI 1.01 to 1.09; and HR 2.08, 95% CI 1.22 to 3.56, respectively). In conclusion, a paradoxical decrease in serum HDL-C levels after statin therapy might be an independent predictor of long-term adverse cardiovascular events in patients with AMI.

DOI： 10.1016/j.amjcard.2014.11.043

Impact of cigarette smoking on coronary plaque composition 査読有り国際誌

Kumagai Soichiro, Amano Tetsuya, Takashima Hiroaki, Waseda Katsuhisa, Kurita Akiyoshi, Ando Hirohiko, Maeda Kazuyuki, Ito Yoshitaka, Ishii Hideki, Hayashi Mutsuharu, Yoshikawa Daiji, Suzuki Susumu, Tanaka Akihito, Matsubara Tatsuaki, Murohara Toyoaki

CORONARY ARTERY DISEASE 26 巻 ( 1 ) 頁： 60 - 65 2015年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Coronary Artery Disease

Objectives Cigarette smoking is associated with atherosclerosis and is an important risk factor for cardiovascular disease. We evaluated the impact of cigarette smoking on coronary plaque composition using integrated backscatter intravascular ultrasound (IB-IVUS).

DOI： 10.1097/MCA.0000000000000168

Positive Vessel Remodeling and Appearance of Pulsatile Wall Motion at Long-Term Follow-Up After Bioresorbable Scaffold Implantation in a Chronic Total Occlusion. 査読有り

Tanaka A, Ruparelia N, Kawamoto H, Latib A, Colombo A

JACC. Cardiovascular interventions 8 巻 ( 12 ) 頁： 1635 - 7 2015年

Practical Approach to Evaluate Asymptomatic Coronary Artery Disease in End-Stage Renal Disease Patients at the Initiation of Dialysis 査読有り

Tanaka Akihito, Sakakibara Masaki, Asada Hiroaki, Tanaka Toshikazu, Ishii Hideki, Murohara Toyoaki

THERAPEUTIC APHERESIS AND DIALYSIS 18 巻 ( 2 ) 頁： 167 - 173 2014年

担当区分：筆頭著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Therapeutic Apheresis and Dialysis

The high prevalence of significant asymptomatic coronary artery disease (CAD) has been reported in patients with end-stage renal disease (ESRD) at the initiation of dialysis. However, the approach to evaluate asymptomatic CAD for these patients has not been established. The aim of this study is to assess the applicability of our practical approach at the initiation of dialysis. We prospectively enrolled 182 consecutive ESRD patients who initiated dialysis. After echocardiography as primary screening, pharmacologic stress thallium-201 scintigraphy and/or coronary angiography (CAG) were performed to diagnose CAD. The patients were classified into two groups: those with coronary artery stenosis by CAG (CAD+ group), those without coronary artery stenosis by CAG or with negative scintigraphy examination (CAD- group). Of the eligible 93 patients without the history of CAD, 22 patients were allocated to the CAD+ group (18 of 26 patients with abnormal echocardiography and 4 of 13 patients with positive scintigraphy examination) and 71 patients to the CAD- group. Patients were followed up for an average of 520±304 days. The event-free survival rate of major adverse cardiac events was significantly lower in the CAD+ group than in the CAD- group (P<0.001). There was no cardiovascular event including major adverse cardiac events, unstable angina, coronary revascularization or stroke in the CAD- group during the first year of dialysis. Patients without CAD diagnosed by our approach had favorable clinical outcomes. Our approach may be useful for screening of occult CAD in ESRD patients at the initiation of dialysis. © 2014 International Society for Apheresis.

DOI： 10.1111/1744-9987.12098

<田中 哲人>

論文 - 田中 哲人

<田中　哲人>

論文 - 田中　哲人